Gilead nears deal to buy Immunomedics for more than $20 billion, WSJ reports

© Reuters. FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen during the outbreak of the coronavirus disease (COVID-19), in California (Reuters) – Gilead Sciences Inc (NASDAQ:) is nearing a deal to buy biopharmaceutical company Immunomedics (NASDAQ:) Inc for more than $ 20 billion in a deal that would further expand Gilead’s portfolio of cancer […]

Continue Reading